Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Viva Biotech HoldingsFRA:VB0 +0.70%47 EV-to-EBITDA is 4.92 as of Jul. 24, 2026, which is 34% below its 10-year median of 7.40. GuruFocus rates FRA:VB0 with a GF Score™ of 47/100 and a GF Value™ of €0.09 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 402 Biotechnology companies, Viva Biotech Holdings ranks better than 66.17% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Viva Biotech Holdings's enterprise value is €337.0 Mil.
Viva Biotech Holdings's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €68.5 Mil. Therefore, Viva Biotech Holdings's EV-to-EBITDA for today is 4.92.
The historical rank and industry rank for Viva Biotech Holdings's EV-to-EBITDA or its related term are showing as below:
FRA:VB0'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -68.34 Med: 7.4 Max: 56.75
Current: 4.84
During the past 10 years, the highest EV-to-EBITDA of Viva Biotech Holdings was 56.75. The lowest was -68.34. And the median was 7.40.
FRA:VB0's EV-to-EBITDA is ranked better than 66.17% of 402
companies
in the Biotechnology industry
Industry Median: 12.2
vs FRA:VB0: 4.84
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Viva Biotech Holdings's PE Ratio (TTM) for today is calculated as:
Viva Biotech Holdings's share price for today is €0.144.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Viva Biotech Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €0.011.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Viva Biotech Holdings EV-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Viva Biotech Holdings's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:VB0 vs VRTX, REGN, ALNY: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Viva Biotech Holdings's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viva Biotech Holdings EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Viva Biotech Holdings's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Viva Biotech Holdings's EV-to-EBITDA falls into.
Viva Biotech Holdings's current Enterprise Value is €337.0 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Viva Biotech Holdings's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €68.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viva Biotech Holdings (FRA:VB0) has a EV-to-EBITDA of 4.92 as of Jul. 24, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Viva Biotech Holdings. This is 34% below median its historical median of 7.40. According to the industry distribution chart, Viva Biotech Holdings ranks #136 out of 402 companies in the Biotechnology industry, placing it in the top 33.8%.
Is Viva Biotech Holdings' EV-to-EBITDA too high?
Viva Biotech Holdings' current EV-to-EBITDA of 4.92 is 34% below median its 10-year median of 7.40. The Biotechnology industry median EV-to-EBITDA is 12.20. Viva Biotech Holdings' value of 4.92 is 59.7% below this industry median. Based on the distribution chart, Viva Biotech Holdings ranks #136 out of 402 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Viva Biotech Holdings has a GF Score™ of 47/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Viva Biotech Holdings' EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Viva Biotech Holdings ranks #136 out of 402 companies for EV-to-EBITDA. This puts Viva Biotech Holdings in the upper half of its industry. The industry median EV-to-EBITDA is 12.20. Viva Biotech Holdings' value of 4.92 is 59.7% below this benchmark. While the company's 10-year median is 7.40 vs. the industry median of 12.20, Viva Biotech Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 12.20, based on 402 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Viva Biotech Holdings's current EV-to-EBITDA of 4.92 is 59.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Viva Biotech Holdings. For the Biotechnology industry, the median EV-to-EBITDA is 12.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Viva Biotech Holdings's current EV-to-EBITDA is 4.92, which is 34% below median its own 10-year median of 7.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viva Biotech Holdings stock overvalued right now?
Based on GuruFocus' analysis, Viva Biotech Holdings (FRA:VB0) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.09, compared to a current price of €0.14 — trading 60% above its estimated fair value. The current EV-to-EBITDA is 4.92, which is 34% below median its 10-year median of 7.40 and 59.7% below the Biotechnology industry median of 12.20. Viva Biotech Holdings' overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Viva Biotech Holdings (FRA:VB0), the current EV-to-EBITDA is 4.92 as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Viva Biotech Holdings (FRA:VB0) Overvalued in 2026?
Based on GuruFocus' analysis, Viva Biotech Holdings stock appears to be overvalued.
The current stock price of €0.14 is trading 60% above its estimated GF Value™ of €0.09.
GuruFocus considers Viva Biotech Holdings to be Significantly Overvalued.
Key valuation signals for FRA:VB0:
EV-to-EBITDA: 4.92 (34% below median its 10-year median of 7.40)
GF Value™: €0.09 vs. price of €0.14 (60% above fair value)
Industry Position: 59.7% below the Biotechnology median (#136 of 402)
No single metric tells the full story. See the FRA:VB0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Viva Biotech Holdings is engaged in providing the structure-based drug discovery services to biotechnology and pharmaceutical customers for their pre-clinical stage drug development. The company operates in three reportable segments, Drug Discovery Services providing structure-based drug discovery services to biotechnology and pharmaceutical customers for their pre-clinical stage drug development; Contract Development Manufacture Organisation providing contract development and manufacturing services for small molecule APIs and intermediates and trading of APIs, intermediates and formulations; and commercialisation services; and Viva BioInnovator making strategic investments in biotechnology startup companies.
47GF Score
Get the complete analysis for FRA:VB0
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:VB0 has been successfully added to your 
